Swiss biotech BioLingus and WuXi AppTec's subsidiary STA Pharmaceutical, a contract development and manufacturing organization, agreed to collaborate on sublingual delivery of drugs in a deal that allows BioLingus' sublingual and buccal delivery technology to be exclusively accessed by WuXi STA.
Italy-based scientists have begun large-scale testing of biotech mosquitoes in a controlled laboratory that mimics their natural environment. The biotech mosquitoes have the doublesex gene mutation, resulting in malformed reproductive organs that prevent female mosquitoes from laying eggs and mouths more like those of male mosquitoes that are incapable of biting or spreading diseases.
An independent data safety monitory board looked at a post-marketing study of Pfizer's rheumatoid arthritis treatment Xeljanz and observed that patients on a twice-daily, 10 mg dose had higher rates of pulmonary embolism and death than a comparison group taking a 5 mg dose twice a day. Pfizer says it is taking steps to transition patients taking the 10 mg dose to a 5 mg dose.
Medtronic has announced a cash tender offer of senior notes amounting to up to $5 billion in outstanding debt. The company's offer includes $2.5 billion in 2.5% senior notes and $600 million in 4.2% senior notes, all due in 2020.
Medtronic is introducing its deep brain stimulation therapy for epilepsy in the US. The system uses an implanted device that releases electrical pulses to the anterior nucleus of the thalamus to reduce partial-onset seizures in patients with resistance to at least three anti-epilepsy medications.
Novo Nordisk has added the Freestyle Libre continuous glucose monitoring system by Abbott to the list of data platforms to be integrated into its new line of connected insulin pens. The Freestyle Libre system will link the pens with the FreeStyle LibreLink mobile app and the LibreView cloud-based system.
Data from a study that evaluated Apollo Endosurgery's OverStitch endoscopic suturing system for endoscopic gastroplasty showed remission of all cases of hypertension and 13 of 17 cases of type 2 diabetes in patients three months after surgery. No mortalities were recorded, and none of the patients required an emergency intervention.
A study in ACS Nano indicates the beating of the heart can be converted into energy through piezoelectric layers attached to a flexible frame, and this energy can then be harnessed to power a pacemaker. This type of heart-powered pacemaker would address a problem seen in other experimental pacemakers, where the rigid structure limits the device's power.
SyncThink's EYE-SYNC device for evaluating patients with possible concussion has been awarded breakthrough designation by the FDA. The device is one of a number of concussion-related technologies that the FDA has reviewed in recent months.
A CE mark was granted to Abbott's Determine HBsAg 2 immunoassay for use in detecting hepatitis B surface antigen. Abbott said its test has an analytical sensitivity of 0.1 IU/mL and determines HBV status within 15 minutes.